EntryPoint Capital LLC Takes $284,000 Position in Artivion, Inc. $AORT

Key Points

• EntryPoint Capital LLC has acquired a new stake in Artivion, Inc., purchasing 11,565 shares valued at approximately $284,000 during the first quarter.
• A number of institutional investors, including Wellington Management Group LLC and American Century Companies Inc., have increased their holdings in Artivion, contributing to an overall institutional ownership of 86.37% in the company.
• Artivion's earnings report showed earnings per share of $0.24 for the quarter, significantly beating the consensus estimate of $0.11, along with a revenue increase of 15.3% compared to the same quarter last year.

EntryPoint Capital LLC bought a new stake in Artivion, Inc. (NYSE:AORT - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,565 shares of the company's stock, valued at approximately $284,000.

A number of other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP raised its position in shares of Artivion by 4.1% in the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock valued at $42,460,000 after purchasing an additional 67,327 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Artivion by 14.9% in the 1st quarter. American Century Companies Inc. now owns 66,406 shares of the company's stock valued at $1,632,000 after acquiring an additional 8,635 shares during the last quarter. Lord Abbett & CO. LLC increased its holdings in shares of Artivion by 31.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company's stock valued at $9,879,000 after acquiring an additional 95,202 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Artivion by 17.5% in the 1st quarter. Russell Investments Group Ltd. now owns 169,594 shares of the company's stock valued at $4,169,000 after acquiring an additional 25,234 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its holdings in shares of Artivion by 27.4% in the 1st quarter. Public Sector Pension Investment Board now owns 119,650 shares of the company's stock valued at $2,941,000 after acquiring an additional 25,698 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AORT has been the subject of a number of research analyst reports. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities upped their price objective on Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. Canaccord Genuity Group upped their price objective on Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Wall Street Zen upgraded Artivion from a "hold" rating to a "buy" rating in a research note on Monday. Finally, Stifel Nicolaus boosted their price target on Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Artivion presently has a consensus rating of "Buy" and a consensus price target of $40.63.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 12,500 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company's stock, valued at $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of the company's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the transaction, the senior vice president directly owned 172,129 shares in the company, valued at $7,637,363.73. The trade was a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 97,790 shares of company stock valued at $3,634,659. 7.60% of the stock is currently owned by company insiders.

Artivion Price Performance

Shares of Artivion stock traded up $0.03 during trading on Thursday, hitting $43.77. The stock had a trading volume of 99,593 shares, compared to its average volume of 443,877. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The firm has a market cap of $2.07 billion, a P/E ratio of -104.21 and a beta of 1.64. The business has a fifty day moving average of $34.51 and a two-hundred day moving average of $29.13. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $45.07.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion's quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.